Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis

NCT03841279 | Completed FDA Device

• 1 other identifier: 18-005455
• Study Type: observational
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

MRI has been shown to be helpful in identifying patients who present with undifferentiated inflammatory arthritis who will develop RA within a one year follow up period. The absence of other clinically apparent symptoms often causes delays in diagnosis of RA. The use of the MRI in conjunction with the physical examination has the potential to reduce diagnostic delay. Earlier diagnosis would allow for earlier treatment implementation for better patient outcomes.

Conditions

Rheumatoid Arthritis

Outcome Measures

Primary Outcomes (1)

• Earlier Diagnosis of RA if MRI is utilized

  To determine if MRI is predictive of later development of RA in patients with undifferentiated inflammatory arthritis; patients with inflammatory arthritis who receive an MRI will have earlier initiation of treatment

  1 year

Interventions

MRI DIAGNOSTIC_TEST

Magnetic resonance imaging (MRI) produces detailed images of the body's internal structures without relying on radiation. It is used to diagnose and also gauge efficacy of treatment.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The target population for this study will be patients with undifferentiated inflammatory arthritis or seronegative rheumatoid arthritis from the outpatient practice of the Division of Rheumatology in Rochester, MN.

You may qualify if:

• ≥ 18 years old
• Undifferentiated inflammatory arthritis suspected to be early RA (≥1 joint with synovitis and ≥1 other tender joint)
• Symptom duration ≤1 year

You may not qualify if:

• Unwillingness or inability to return to Mayo Clinic Rochester for research follow-up visits
• Current or previous use of DMARDS
• Taking ≥10 mg of prednisone a day
• Contraindications to contract enhanced MRI
• History of another definite autoimmune or inflammatory rheumatic disease
• History of psoriasis
• History of inflammatory bowel disease
• Unsuitably as deemed by the principal investigator

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Kerry Wright, MBBS

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 12, 2019
• First Posted: February 15, 2019
• Study Start: January 1, 2019
• Primary Completion: June 17, 2023
• Study Completion: December 31, 2025
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)